Back to top
more

Sangamo Therapeutics (SGMO)

(Real Time Quote from BATS)

$0.25 USD

0.25
5,523,525

0.00 (-1.85%)

Updated Apr 9, 2026 09:42 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value A Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Wall Street Analysts Think Sangamo (SGMO) Could Surge 64%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Sangamo (SGMO) points to a 64.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of 2.94% and 5.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Sangamo Therapeutics (SGMO) Q3 Earnings Expected to Decline

by Zacks Equity Research

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Biogen (BIIB) Stock Up This Year So Far on Aduhelm Approval

by Zacks Equity Research

Biogen's (BIIB) new Alzheimer's drug, Aduhelm should bring in huge revenues, if successfully commercialized.

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -10.00% and -6.21%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Sangamo Therapeutics (SGMO) Q2 Earnings Expected to Decline

by Zacks Equity Research

Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

by Zacks Equity Research

The EMA validates BioMarin's (BMRN) marketing application for valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.

Zacks Equity Research

BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU

by Zacks Equity Research

Biomarin Pharmaceutical's (BMRN) new MAA in EU includes 52 weeks' data from the phase III GENEr8-1 study, along with four and three-year follow-up data from the ongoing phase I/II dose escalation study.

Zacks Equity Research

Biogen (BIIB) 2nd Eye Disease Gene Therapy Misses Study Goal

by Zacks Equity Research

Biogen's (BIIB) rare, inherited retinal disease gene therapy candidate, timrepigene emparvovec, fails to meet the primary endpoint in a phase III study.

Zacks Equity Research

BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review

by Zacks Equity Research

The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.